Payment overview · 2025
General Payments
$111.82
6 reported records · 4 companies
Healthcare provider profile · identity verified
Robert Makishi
Allopathic & Osteopathic Physicians|Family Medicine · CHILLICOTHE, OH · NPI 1144632092
Verified facts
What the public records show
CMS Open Payments records show Robert Makishi received $111.82 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.69 | 36.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.83 | 27.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.41 | 21.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.89 | 14.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $111.82 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.69 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.69 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
176 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 202 |
| Omeprazole | Omeprazole | 377 | 115 |
| Gabapentin | Gabapentin | 352 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 105 |
| Lisinopril | Lisinopril | 328 | 111 |
| Losartan Potassium | Losartan Potassium | 271 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 69 |
| Potassium Chloride | Potassium Chloride | 186 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 62 |
| Furosemide | Furosemide | 177 | 59 |
| Ozempic | Semaglutide | 176 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 164 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 58 |
| Metformin Hcl | Metformin Hcl | 158 | 49 |
| Sertraline Hcl | Sertraline Hcl | 149 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 44 |
| Allopurinol | Allopurinol | 140 | 33 |
| Trazodone Hcl | Trazodone Hcl | 136 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 47 |
| Prednisone | Prednisone | 114 | 69 |
| Simvastatin | Simvastatin | 114 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 32 |
| Farxiga | Dapagliflozin Propanediol | 104 | 22 |
| Pregabalin | Pregabalin | 103 | 18 |
| Montelukast Sodium | Montelukast Sodium | 102 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 101 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 30 |
| Carvedilol | Carvedilol | 93 | 27 |
| Tramadol Hcl | Tramadol Hcl | 92 | 20 |
| Eliquis | Apixaban | 91 | 26 |
| Glipizide | Glipizide | 91 | 32 |
| Alendronate Sodium | Alendronate Sodium | 85 | 24 |
| Lorazepam | Lorazepam | 83 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 23 |
| Metformin Hcl Er | Metformin Hcl | 77 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 72 | 61 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 71 | 20 |
| Atenolol | Atenolol | 69 | 19 |
| Diazepam | Diazepam | 69 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 22 |
| Meloxicam | Meloxicam | 62 | 19 |
| Famotidine | Famotidine | 61 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 14 |
| Glimepiride | Glimepiride | 59 | 18 |
| Buspirone Hcl | Buspirone Hcl | 58 | 21 |
| Alprazolam | Alprazolam | 57 | 17 |
| Bupropion Xl | Bupropion Hcl | 51 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 22 |
| Jardiance | Empagliflozin | 51 | 11 |
| Ibuprofen | Ibuprofen | 50 | 19 |
| Spironolactone | Spironolactone | 50 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Ezetimibe | Ezetimibe | 44 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 15 |
| Topiramate | Topiramate | 43 | 12 |
| Azelastine Hcl | Azelastine Hcl | 41 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | 11 |
| Naproxen | Naproxen | 41 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Glipizide Er | Glipizide | 37 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 11 |
| Baclofen | Baclofen | 36 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 35 | 33 |
| Estradiol | Estradiol | 35 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 14 |
| Azithromycin | Azithromycin | 33 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 14 |
| Mirtazapine | Mirtazapine | 33 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | 11 |
| Cephalexin | Cephalexin | 32 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 11 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Nabumetone | Nabumetone | 30 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 16 |
| Valsartan | Valsartan | 29 | 12 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 11 |
| Fluconazole | Fluconazole | 28 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | 11 |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 12 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Aripiprazole Odt | Aripiprazole | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dilantin | Phenytoin | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $111.82 · 6 records | ABBVIE INC. | AIRSUPRA, FREESTYLE LIBRE 3, QULIPTA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error